Fentanyl (Fentanyl) Patent Expiration, LOE Window & CMS Spending

Fentanyl (Fentanyl) by Teva Pharmaceuticals: Off-Patent Genericized (AB Competition), 4 AB generics, $101.6M 2024 CMS Part D & Medicaid spend, and $465 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeva Pharmaceuticals
FDA Application & PathwayN020195 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$101.6M
2024 Medicare Part D Spend$92.4M
2024 Medicaid Spend$9.2M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($465 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Teva Pharmaceuticals across sibling Meru public-data platforms.